Tiprelestat is under clinical development by Proteo Biotech and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Tiprelestat’s likelihood of approval (LoA) and phase transition for Inflammation took place on 26 Aug 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Tiprelestat Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Tiprelestat overview

Tiprelestat (Elafin) is under development for the treatment of inflammatory complications associated with post-operative esophageal carcinoma and transthoracic esophagectomy, ischemia-reperfusion injury, pulmonary arterial hypertension, ventilator-induced lung injury in premature babies, vascular damage, lung transplant, life-threatening infections and inflammation of cardiac muscle after coronary bypass operations. It is administered through intravenous and subcutaneous route. Elafin is a serine protease inhibitor. The drug candidate was also under development for kidney transplantation, lung transplant rejection and thromboembolic pulmonary hypertension.

Proteo Biotech overview

Proteo Biotech (Proteo), a subsidiary of Proteo Inc, is developer and marketer of nature identical compounds for biological and medical research, and for use as pharmaceuticals. The company develops pharmaceuticals based on body’s immune system to fight inflammatory diseases. It provides product pipeline such as elafin, a soluble endogenous protein produced by the human body and acts as a natural inhibitor of tissue destroying enzymes. Proteo’s pre-clinical research areas includes pulmonary arterial hypertension, ventilator-induced injury of the immature lung in premature babies, chronic lung transplant rejection, vascular damages and life threatening infections. It offers services such as research and development, clinical development and preclinical research. Proteo is headquartered in Kiel, Schleswig-Holstein, Germany.

Quick View Tiprelestat LOA Data

Report Segments
  • Innovator
Drug Name
  • Tiprelestat
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Cardiovascular
  • Immunology
  • Infectious Disease
  • Respiratory
Key Developers
  • Sponsor Company: Proteo Biotech
  • Originator: Proteo Biotech
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.